We are a late-stage pharmaceutical company focused on addressing diseases of the central nervous system (CNS).

Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward our initial target indication, which is adjunctive treatment for major depressive disorder (MDD) in adults.

Depression represents the largest cause of disability around the world¹. Our dedicated team is focused on moving REL-1017 forward as a potentially transformational option in the treatment of MDD.

Based on our Phase 1 and Phase 2 studies, we believe there is a real potential for REL-1017 to treat MDD safely, effectively, and more quickly than is currently possible with a well-tolerated, oral, once-daily tablet. REL-1017 received Fast Track Designation and is moving forward with pivotal phase 3 studies as an adjunctive treatment for MDD in adults.

We are growing our company accordingly as we execute upon plans for registration studies for REL-1017 and have assembled an experienced development team to move this promising program.